Evidence map›Paper›PMID 30685808›Full record

Trial reportEuropean journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology2019

G-CSF-primed haplo-identical HSCT with intensive immunosuppressive and myelosuppressive treatments does not increase the risk of pre-engraftment bloodstream infection: a multicenter case-control study.

Jinhua Ren, Qiaoxian Lin, Weimin Chen, Congmeng Lin, Yuxin Zhang, Cunrong Chen, Shaozhen Chen, Xiaohong Yuan, Ping Chen, Xiaofeng Luo and 12 more

Registry-linked trialAbstract readClinical TrialComparative StudyMulticenter Study
PubMed Publisher
In one paragraph

Trial report in European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT02328950 (A 5 Day Course of Fludarabine and Cytarabine Followed by Full Intensity Allogeneic Stem Cell Transplantation), which is not on this map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT02328950 unknown statusnot on this map

A 5 Day Course of Fludarabine and Cytarabine Followed by Full Intensity Allogeneic Stem Cell Transplantation (FA5-Bucy) in Treating Patients With High-risk, Recurrent or Refractory Acute Leukemia and Advanced Myelodysplastic Syndrome

TypeobservationalSponsorFujian Medical UniversityRan2014 to 2017Enrolled50ConditionsMyelodysplastic Syndromes, Leukemia, Myeloid, Acute, Precursor Cell Lymphoblastic Leukemia-LymphomaArmsFludarabine and Cytarabine followed by IV busulfan and cyclophosphamide
3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

22 authors.

Jinhua RenDepartment of Hematology, Fujian Institute of Hematology, Fujian Provincial Key Laboratory of Hematology, Fujian Medical University Union Hospital, No. 29 Xinquan Rd, 350001, Fuzhou, Fujian, People's Republic of China.
Qiaoxian LinDepartment of Hematology, Fujian Institute of Hematology, Fujian Provincial Key Laboratory of Hematology, Fujian Medical University Union Hospital, No. 29 Xinquan Rd, 350001, Fuzhou, Fujian, People's Republic of China.
Weimin ChenDepartment of Hematology, Fujian Provincial Hospital, Fuzhou, 350001, Fujian, People's Republic of China.
Congmeng LinDepartment of Hematology, Zhangzhou Affiliated Hospital of Fujian Medical University, Zhangzhou, 363000, Fujian, People's Republic of China.
Yuxin ZhangDepartment of Hematology, Fujian Institute of Hematology, Fujian Provincial Key Laboratory of Hematology, Fujian Medical University Union Hospital, No. 29 Xinquan Rd, 350001, Fuzhou, Fujian, People's Republic of China.
Cunrong ChenDepartment of Intensive Care Unit, Fujian Medical University Union Hospital, Fuzhou, 350001, Fujian, People's Republic of China.
Shaozhen ChenDepartment of Hematology, Fujian Institute of Hematology, Fujian Provincial Key Laboratory of Hematology, Fujian Medical University Union Hospital, No. 29 Xinquan Rd, 350001, Fuzhou, Fujian, People's Republic of China.
Xiaohong YuanDepartment of Hematology, Fujian Institute of Hematology, Fujian Provincial Key Laboratory of Hematology, Fujian Medical University Union Hospital, No. 29 Xinquan Rd, 350001, Fuzhou, Fujian, People's Republic of China.
Ping ChenDepartment of Hematology, Fujian Institute of Hematology, Fujian Provincial Key Laboratory of Hematology, Fujian Medical University Union Hospital, No. 29 Xinquan Rd, 350001, Fuzhou, Fujian, People's Republic of China.
Xiaofeng LuoDepartment of Hematology, Fujian Institute of Hematology, Fujian Provincial Key Laboratory of Hematology, Fujian Medical University Union Hospital, No. 29 Xinquan Rd, 350001, Fuzhou, Fujian, People's Republic of China.
Yun LinDepartment of Hematology, Fujian Provincial Hospital, Fuzhou, 350001, Fujian, People's Republic of China.
Lvying ShenDepartment of Hematology, Zhangzhou Affiliated Hospital of Fujian Medical University, Zhangzhou, 363000, Fujian, People's Republic of China.
Mengxian GuoDepartment of Hematology, Zhangzhou Affiliated Hospital of Fujian Medical University, Zhangzhou, 363000, Fujian, People's Republic of China.
Qiuru ChenDepartment of Hematology, Fujian Institute of Hematology, Fujian Provincial Key Laboratory of Hematology, Fujian Medical University Union Hospital, No. 29 Xinquan Rd, 350001, Fuzhou, Fujian, People's Republic of China.
Min XiaoDepartment of Hematology, Fujian Institute of Hematology, Fujian Provincial Key Laboratory of Hematology, Fujian Medical University Union Hospital, No. 29 Xinquan Rd, 350001, Fuzhou, Fujian, People's Republic of China.
Yongquan ChenDepartment of Hematology, Fujian Institute of Hematology, Fujian Provincial Key Laboratory of Hematology, Fujian Medical University Union Hospital, No. 29 Xinquan Rd, 350001, Fuzhou, Fujian, People's Republic of China.
Xueqiong WuDepartment of Hematology, Fujian Institute of Hematology, Fujian Provincial Key Laboratory of Hematology, Fujian Medical University Union Hospital, No. 29 Xinquan Rd, 350001, Fuzhou, Fujian, People's Republic of China.
Yanling ZengDepartment of Hematology, Fujian Institute of Hematology, Fujian Provincial Key Laboratory of Hematology, Fujian Medical University Union Hospital, No. 29 Xinquan Rd, 350001, Fuzhou, Fujian, People's Republic of China.
Zhizhe ChenDepartment of Hematology, Fujian Institute of Hematology, Fujian Provincial Key Laboratory of Hematology, Fujian Medical University Union Hospital, No. 29 Xinquan Rd, 350001, Fuzhou, Fujian, People's Republic of China.
Xudong MaDepartment of Hematology, Zhangzhou Affiliated Hospital of Fujian Medical University, Zhangzhou, 363000, Fujian, People's Republic of China.
Jianda HuDepartment of Hematology, Fujian Institute of Hematology, Fujian Provincial Key Laboratory of Hematology, Fujian Medical University Union Hospital, No. 29 Xinquan Rd, 350001, Fuzhou, Fujian, People's Republic of China.
Ting YangDepartment of Hematology, Fujian Institute of Hematology, Fujian Provincial Key Laboratory of Hematology, Fujian Medical University Union Hospital, No. 29 Xinquan Rd, 350001, Fuzhou, Fujian, People's Republic of China. yang.hopeting@gmail.com.

Funding

Fujian Provincial Key Laboratory Foundation of Hematology 2009J1004National and Fujian Provincial Key Clinical Specialty Discipline Construction Program, China, National High Technology Research and Development Program of China, 863 program 2012AA02A505National Natural Science Foundation of China 81570162,81870138National Natural Science Foundation of China 81700131National Public Health Grand Research Foundation 201202017Natural Science Foundation of Fujian Province 2017Y9017, 2017Y9037, 2017Y9056, 2018Y0031
6 · The paper itself

Abstract

A multicenter retrospective study in 131 patients (44 females/87 males) with hematological disorders who underwent G-CSF-primed/haplo-identical (Haplo-ID) (n = 76) or HLA-identical (HLA-ID) HSCT (n = 55) from February 2013 to February 2016 was conducted to compare the incidence and risk factors for pre-engraftment bloodstream infection (PE-BSI). In the Haplo-ID group, 71/76 patients with high-risk (n = 28) or relapsed/refractory hematological malignancies (n = 43) received FA5-BUCY conditioning (NCT02328950). All received trimethoprim-sulfamethoxazole (TMP-SMX) prophylaxis. Blood cultures and catheter tip cultures were obtained to confirm the BSI. PE-BSI was detected in 24/131 HSCT patients (18/76 in Haplo-ID and 6/55 in HLA-ID) after 28 febrile neutropenic episodes. Among 28 isolates for the 24 patients, 21 (75%) were G

Indexed as

AdolescentAdultAntibiotic ProphylaxisAnti-Infective AgentsBacteremiaCase-Control StudiesChildChild, PreschoolFemaleGranulocyte Colony-Stimulating FactorHematologic NeoplasmsHematopoietic Stem Cell TransplantationHumansImmunosuppressive AgentsIncidenceInfantAnti-Infective AgentsGranulocyte Colony-Stimulating FactorImmunosuppressive AgentsBloodstream infectionHaplo-identicalHSCTImmunosuppressive and myelosuppressive treatmentsPre-engraftment

Identifiers

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.